S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Enanta Pharmaceuticals (ENTA) Stock Forecast, Price & News

+1.34 (+3.51%)
(As of 05/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
277,498 shs
Average Volume
235,864 shs
Market Capitalization
$817.54 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Enanta Pharmaceuticals logo

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$97.07 million
Book Value
$17.31 per share


Net Income
$-79 million
Net Margins
Pretax Margin




Free Float
Market Cap
$817.54 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.26 out of 5 stars

Medical Sector

309th out of 1,427 stocks

Pharmaceutical Preparations Industry

118th out of 683 stocks

Analyst Opinion: 3.4Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

Is Enanta Pharmaceuticals a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Enanta Pharmaceuticals stock.
View analyst ratings for Enanta Pharmaceuticals
or view top-rated stocks.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Enanta Pharmaceuticals

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its quarterly earnings data on Monday, May, 9th. The biotechnology company reported ($1.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by $0.20. Enanta Pharmaceuticals had a negative net margin of 122.68% and a negative trailing twelve-month return on equity of 28.80%. During the same quarter in the previous year, the business earned ($1.09) earnings per share.
View Enanta Pharmaceuticals' earnings history

What price target have analysts set for ENTA?

7 analysts have issued 1 year price targets for Enanta Pharmaceuticals' shares. Their forecasts range from $44.00 to $103.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $74.14 in the next twelve months. This suggests a possible upside of 87.8% from the stock's current price.
View analysts' price targets for Enanta Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Enanta Pharmaceuticals' key executives?
Enanta Pharmaceuticals' management team includes the following people:
  • Dr. Jay R. Luly, Pres, CEO & Director (Age 66, Pay $1.23M)
  • Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 67, Pay $652.39k)
  • Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 70, Pay $729.75k)
  • Ms. Tara Lynn Kieffer Ph.D., Sr. VP of New Product Strategy & Devel. (Age 44, Pay $496.85k)
  • Mr. Brendan Luu, Sr. VP of Bus. Devel.
  • Ms. Jennifer Viera, Sr. Director of Investor Relations & Corp. Communications
  • Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 68)
  • Dr. Nathalie Adda M.D., Consultant (Age 56) (LinkedIn Profile)
What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

3 employees have rated Enanta Pharmaceuticals CEO Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among Enanta Pharmaceuticals' employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (17.13%), Vanguard Group Inc. (7.67%), Farallon Capital Management LLC (7.48%), State Street Corp (6.32%), RA Capital Management L.P. (4.66%) and Northern Trust Corp (4.48%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, Jay R Luly, Nathalie Adda and Paul J Mellett.
View institutional ownership trends for Enanta Pharmaceuticals

Which major investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Granahan Investment Management LLC, Renaissance Technologies LLC, Northern Trust Corp, Acadian Asset Management LLC, Candriam Luxembourg S.C.A., Vanguard Group Inc., and Citigroup Inc.. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, Jay R Luly, and Nathalie Adda.
View insider buying and selling activity for Enanta Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Enanta Pharmaceuticals stock?

ENTA stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Deep Track Capital LP, State Street Corp, Fairmount Funds Management LLC, Invesco Ltd., BlackRock Inc., Walleye Capital LLC, and Walleye Capital LLC.
View insider buying and selling activity for Enanta Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $39.47.

How much money does Enanta Pharmaceuticals make?

Enanta Pharmaceuticals has a market capitalization of $817.54 million and generates $97.07 million in revenue each year. The biotechnology company earns $-79 million in net income (profit) each year or ($5.52) on an earnings per share basis.

How many employees does Enanta Pharmaceuticals have?

Enanta Pharmaceuticals employs 155 workers across the globe.

What is Enanta Pharmaceuticals' official website?

The official website for Enanta Pharmaceuticals is www.enanta.com.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at (617) 607-0800, via email at [email protected], or via fax at 617-607-0530.

This page was last updated on 5/29/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.